GT Biopharma, Inc.

Contributing Author

Recent Articles by GT Biopharma, Inc.

Oct-23	GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies GTBP GlobeNewswire
Oct-08	GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies GTBP GlobeNewswire
Oct-06	GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit GTBP GlobeNewswire
Sep-04	GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference GTBP GlobeNewswire
Aug-14	GT Biopharma Reports Second Quarter 2025 Financial Results GTBP GlobeNewswire
Aug-11	GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 GTBP GlobeNewswire
Jun-13	GT Biopharma Appoints New Member to its Board of Directors GTBP GlobeNewswire
May-19	GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals GTBP GlobeNewswire
May-15	GT Biopharma Appoints New Member to its Board of Directors GTBP GlobeNewswire
May-14	GT Biopharma Appoints New Member to its Board of Directors GTBP GlobeNewswire